Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
Berzosertib 270 mg/m<sup>2</sup> and irinotecan 180 mg/m<sup>2</sup> was the RP2D. The combination is associated with manageable side effects and promising disease activity in ATM mutant solid tumors.
Authors
- Angelina M. Parise (ORCID: https://orcid.org/0000-0003-0207-2510)
- John C. Schmitz (ORCID: https://orcid.org/0000-0001-6321-9606)
- Bella S. Guerrouahen (ORCID: https://orcid.org/0000-0003-4124-4389)
- Katherine V. Ferry‐Galow
- Dana B. Cardin (ORCID: https://orcid.org/0000-0002-0269-9615)
- Leonard J. Appleman (ORCID: https://orcid.org/0000-0003-4951-7388)
- Ting‐Chia Chang (ORCID: https://orcid.org/0000-0003-1318-0701)
- James M. Cleary (ORCID: https://orcid.org/0000-0001-7213-3951)
- Rashmi Verma (ORCID: https://orcid.org/0000-0002-8786-0104)
- Alejandro Contreras (ORCID: https://orcid.org/0000-0001-6668-823X)
- Jan H. Beumer (ORCID: https://orcid.org/0000-0002-8978-9401)
- Diwakar Davar (ORCID: https://orcid.org/0000-0002-7846-8055)
- Susan M. Christner
- Timothy F. Burns (ORCID: https://orcid.org/0000-0002-8685-3762)
- Joshua J. Deppas (ORCID: https://orcid.org/0000-0002-9093-7459)
- Geoffrey Ira Shapiro (ORCID: https://orcid.org/0000-0002-3331-4095)
- Kristen K. Ciombor (ORCID: https://orcid.org/0000-0002-8992-9515)
- Steven Gore (ORCID: https://orcid.org/0009-0004-5227-4502)
- Shahanawaz Jiwani (ORCID: https://orcid.org/0000-0002-4717-8637)
- Jason J. Luke (ORCID: https://orcid.org/0000-0002-1182-4908)
- Manik Amin (ORCID: https://orcid.org/0000-0001-8467-6152)
- Elizabeth J. Davis (ORCID: https://orcid.org/0000-0001-7626-2435)
- Jianxia Guo (ORCID: https://orcid.org/0000-0002-2732-8220)
- Christopher J. Bakkenist (ORCID: https://orcid.org/0000-0001-9672-0886)
- Michael Suchko (ORCID: https://orcid.org/0009-0008-4393-5750)
- Jingxiao Jin (ORCID: https://orcid.org/0000-0002-4029-650X)
- Liqing Li (ORCID: https://orcid.org/0000-0001-8297-309X)
- Saiama N. Waqar (ORCID: https://orcid.org/0000-0002-7069-5456)
- Liza Cosca Villaruz (ORCID: https://orcid.org/0000-0001-7456-523X)
- Jonathan Wesley Riess (ORCID: https://orcid.org/0000-0001-7370-7304)
- Edward Chu (ORCID: https://orcid.org/0000-0002-0908-5325)
- John C. Rhee
- Hong Wang (ORCID: https://orcid.org/0000-0003-0477-2908)
- Edward Kim (ORCID: https://orcid.org/0000-0002-8660-7465)
- James J. Lee (ORCID: https://orcid.org/0000-0001-6749-9350)
- E. Claire Dees
Institutions
- University of North Carolina at Chapel Hill (US)
- Leidos (United States) (US)
- University of Maryland, Baltimore (US)
- Montefiore Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Pittsburgh (US)
- Washington University in St. Louis (US)
- University of Chicago (US)
- Sidney Kimmel Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- UPMC Hillman Cancer Center (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
- UC Davis Comprehensive Cancer Center
- University of Baltimore (US)
- University of California, Davis (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1002/cncr.70157
- Citations
- 1
- Primary Topic
- DNA Repair Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.81